Walla Dempsey

TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.

TL;DR: In this article, the authors compared the efficacy of interferon beta-1a in combination with remdesivir in hospitalised patients with SARS-CoV-2 infection, as confirmed by a positive RT-PCR test, and the primary outcome was time to recovery, defined as the first day that a patient attained a category 1, 2, or 3 score on the eight-category ordinal scale.

TL;DR: The study was halted after enrollment of 43 subjects and before any subject received their third scheduled dose of parvovirus B19 vaccine because of 3 unexplained cutaneous events.

TL;DR: The primary outcome was the difference in mechanical ventilation-free survival by day 29 between the two treatment groups in the modified intention-to-treat population.

TL;DR: While at least 70% agreement was reached on most endpoints, the process identified areas for further evaluation and standardization within the context of ongoing clinical studies.